PARTICULARS TO APPEAR ON THE OUTER PACKAGE - CARTON

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Drontal Plus XL Flavour Tablets for Dogs

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains:

175 mg praziquantel, 504 mg pyrantel embonate, 525 mg febantel

3. PACKAGE SIZE

2 tablets for dogs / 1 tablet = 35 kg
8 tablets for dogs / 1 tablet = 35 kg
48 tablets for dogs / 1 tablet = 35 kg
96 tablets for dogs / 1 tablet = 35 kg

4. TARGET SPECIES

Dogs

5. INDICATIONS

For the control of tapeworms and roundworms of adult dogs.

6. ROUTES OF ADMINISTRATION

Oral use.

The recommended dose is 1 tablet per 35 kg bodyweight.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25°C. Any part-used tablets should be discarded.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Vetoquinol UK Limited

14. MARKETING AUTHORISATION NUMBERS

Vm 08007/5044

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS – BLISTER STRIP

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Drontal Plus XL Flavour Tablets for Dogs

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

175 mg Praziquantel
504 mg Pyrantel embonate
525 mg Febantel

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Drontal Plus XL Flavour Tablets for Dogs

2. Composition

Each tablet contains:

Active substances:

175 mg praziquantel, 504 mg pyrantel embonate, 525 mg febantel

Excipients:

408 mg artificial beef flavour irradiated

Pale brown to brown oval shaped divisible tablet scored on both sides.

3. Target species

Dogs.

4. Indications for use

Worms controlled include:

Ascarids: Toxocara canis, Toxascaris leonina (adult and late immature forms).

Hookworms: Uncinaria stenocephala, Ancylostoma caninum (adults)

Whipworms: Trichuris vulpis (adults)

Tapeworms: Echinococcus spp. Taenia spp. and Dipylidium caninum (adult and immature forms).

5. Contraindications

Do not exceed stated dose when treating pregnant bitches.

Do not use simultaneously with piperazine compounds. Concurrent use with other cholinergic compounds is not recommended.

6. Special warnings

Special warnings:

Fleas serve as intermediate hosts for one common type of tapeworm - *Dipylidium caninum*. Tapeworm infestation is certain to re-occur unless control of intermediate hosts such as fleas, mice etc. is undertaken.

Since it contains praziquantel, the veterinary medicinal product is effective against *Echinococcus multilocularis,* which does not occur in the UK or Ireland but is becoming more common in some European countries. As a precautionary measure to prevent establishment of *E multilocularis* in the UK and Ireland, it is recommended that all dogs entering the country be treated with praziquantel.

Special precautions for safe use in the target species:

Any part-used tablets should be discarded.
Do not exceed the stated dose when treating pregnant bitches.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
In the interests of good hygiene, persons administering the tablets directly to a dog, or by adding them to the dog's food, should wash their hands afterwards.

Pregnancy:

Consult a veterinary surgeon before treating pregnant animals for roundworms.

Lactation:

This veterinary medicinal product may be used during lactation (see Interactions below).

Interaction with other medicinal products and other forms of interaction:

Do not use simultaneously with piperazine.
Concurrent use with other cholinergic compounds is not recommended.

Overdose:

The veterinary medicinal product is well tolerated in dogs. In safety studies doses of 5 x or greater gave rise to occasional vomiting.

Major incompatibilities:

None known

7. Adverse events

Dog:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Digestive tract disorders (e.g., vomiting and diarrhoea)[1], Anorexia, Lethargy, Hyperactivity.

[1]Mild and transient.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Dosage

For oral administration only.

Dosages are as follows

Bodyweight (kg)	Table Quantity
17.5	½
>17.5 – 35	1
>35 – 52.5	1½
>52.5 – 70	2

The veterinary medicinal product should be used to achieve accurate dosing in dogs weighing less than 17.5 kg.

9. Advice on correct administration

The tablet(s) can be given directly to the dog or disguised in food. No starvation is needed before, or after, treatment.

For routine treatment, a single dose is recommended.

For the control of *Toxocara*, nursing bitches should be dosed 2 weeks after giving birth and every 2 weeks until weaning.

For routine control, adult dogs should be treated every 3 months. In the event of a heavy roundworm infestation, a repeat dose should be given after 14 days.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Do not store above 25ºC. Any part-used product should be discarded.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and blister after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product not subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 08007/5044

Container material:

- PCTFE/PVC-aluminium foil strip
- OPA/Alu/HDPE-aluminium foil strip

Container colour: White and silver

Container sizes: Cartons containing 2, 8, 48 and 96 tablets

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

Vetoquinol UK Limited, Steadings Barn, Pury Hill Business Park, Nr. Alderton, Towcester, Northamptonshire, NN12 7LS

+44 (0)1280 814500

Manufacturer responsible for batch release:
- KVP Pharma + Veterinär Produkte GmbH, Projensdorfer Str. 324, 24106 Kiel, Germany
- EUROPHARTECH, 34 rue Henri Matisse, 63370 Lempdes, France

17. Other information

NFA-VPS

Gavin Hall
Approved: 03 September 2026